CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 576 enrolled
Drug / intervention
WATCHMAN LAA Closure Technologydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01760291
NCT01760291N/ACompleted
CompareCT.gov

Continued Access to PREVAIL (CAP2)- WATCHMAN Left Atrial Appendage (LAA) Closure Technology

Boston Scientific Corporation·interventional·Posted Jan 4, 2013·Updated Mar 29, 2022

In Brief

A clinical study evaluating WATCHMAN LAA Closure Technology for Atrial Fibrillation. Completed, enrolled 576 participants across 3 sites.

Detailed Summary

To provide additional information about the safety and efficacy of the WATCHMAN LAA Closure Technology

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 4, 2013
Enrollment StartSep 1, 2012
Primary CompletionApr 1, 2019
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 13.5 years ago

Interventions

WATCHMAN LAA Closure Technologydevice